Cannabis White Papers & Research

We’re excited to share this Cannabis White Papers & Research section to highlight some of the transformational research validating the anecdotal evidence that already exists. Here you will find a variety of white papers, professional reports, peer-reviewed articles, clinical trials and academic research studies. Some will include full text, some abstracts that point to the original published work.

We recognize the importance that patients, parents, doctors, lawmakers and business professionals place on scientific research when it comes to making decisions that impact our families, communities, public policy, economy and society at large. Therefore, we place a premium on integrity when it comes to providing educational content and will not accept money to publish commercially biased papers here.

However, despite growing acceptance and legitimacy, scientific study about cannabis remains constrained by federal laws and social stigma. This often deters funding from traditional grant makers, government agencies or institutional sources leaving study authors no choice but to accept research grants from commercial entities with vested interests in the outcome of the study, which results in potential for conflicts of interest. We will make every effort to disclose any possible conflicts as we become aware of them.

We welcome your feedback and recommendations, particularly if you are aware of more current studies than those listed here. If you are working within in the medical, professional or scientific communities, know about a groundbreaking story or and have a clinical or academic study of your own to share, we also welcome submissions. Please Contact Us to submit a study or let us know what you’re looking for and we’ll do our best to find it.

Australia is becoming a hot spot for cannabis research. Recently, the world’s first clinical trial of cannabis for cancer began thanks to Chris O’Brein Lifehouse and the University of Sidney. The trial will test whether or not cannabis has an effect on chemotherapy-induced nausea and vomiting in 80 patients. Now, researchers in Perth are turning…

As the first comprehensive study to be conducted by a Federally sanctioned institution, the NAS study has potential to expose the fallacy of the classification of cannabis as a Schedule 1 controlled substance.